Entacapone

Trade names

• COMTAN

Actions

• Selective and reversible inhibitor of the enzyme catechol-O-methyltransferase (COMT).

Route of Administration

Oral

Bioavailability

35%

Plasma protein binding

98%

Half-life

0.4–0.7 hours

Metabolism

Hepatic

Elimination

Biliary 90%, renal 10%

Important side-effects

Nausea and vomiting.

Excessive sweating.

Urinary retention.

Hepatitis with cholestatic features.

Recommended dose

A 200 mg tablet is given with every L-Dopa dose.

The maximum recommended tose of entacapone is 2000 mg / day.

Renal impairment

Caution is advised in treating patients with severe renal function impairment with entacapone.

Hepatic impairment

Dose adjustment might be necessary in patients with moderate hepatic function impairment.

Entacapone should not be administered in patients with severe hepatic function impairment.